An era of open information in healthcare is now under way. Healthcare stakeholders now have access to promising new threads of knowledge. Pharmaceutical industry and academic experts, payers, and providers are now analyzing big data with state-of-the-art predictive modeling and simulation techniques to obtain deep insights. Pair this with the exciting movement of personalized medicine, the ability to customize therapies based on the context of each individual patient's genetic content, and we now have the incredible opportunity to get even closer to exquisite precision in disease diagnosis and treatment. This panel will bring together thought leaders from across the field to explore big data’s full potential, and its application to the field of personalized medicine.
Patrick has more than 14 years of consulting experience and has worked in North America, Europe, and Asia. He co-leads Bain’s R&D practice and helps clients across industries significantly improve their R&D performance.
In addition, Patrick is a leader in Bain’s Healthcare practice. He has worked with leading pharmaceutical and medical device companies on a wide variety of strategic and operational projects.
In healthcare, Patrick has led a wide variety of strategic and operational projects with leading pharmaceutical and medical device companies. These projects have included R&D redesign, clinical development optimization and growth strategies across many therapeutic areas and geographies.
He has authored two Bain publications: Bringing pharma R&D back to health and Reengineering medtech R&D.
Patrick received a PhD from Oxford University, a MBA with distinction from Harvard Business School and BA magna cum laude from Harvard University.
Andrew A. Radin has been the Chief Technology Officer at several early stage companies where he has managed teams as small as five geeks in an apartment to over a hundred technologists distributed around the world. Andrew also consults for a venture capital firm, and has provided technical diligence and mentoring for a number of growing startups. As Chief Executive Officer of twoXAR, he developed our proprietary algorithm and is focused on refining the product, building the team, and fundraising. Andrew studied biomedical informatics at Stanford University through Stanford's SCPD graduate program and holds Master of Science and Bachelor of Science degrees in computer science from Rochester Institute of Technology.
Nate Russell is Vice President of Corporate Strategy and Business Development Evaluations at Pfizer. Nate's organization is charged both with shaping Pfizer's longer-term enterprise strategy as well as evaluating specific business development opportunities in support of Pfizer's identified objectives for both the in-line and pipeline portfolios. Nate is a member of Pfizer's Strategy, Portfolio, and Commercial Operations Leadership Team.
With more than 10 years of experience at Pfizer, Nate has held roles in R&D portfolio management, U.S. commercial operations, U.S. marketing, business development evaluation, and now also corporate strategy. He joined the company in 2004 and spent the early part of his career in Portfolio & Decision Analysis (PDA) where he played a significant role helping the company to not only identify the optimal development plan for individual assets, but also to prioritize those plans versus other possible R&D investments. He also played a leading role in developing a quantitative approach to prioritize US product operating plans and reallocate $5 billion of annual funds over a portfolio of 30 products, creating $6 billion in incremental value.
Nate later joined the U.S. in-line organization as a Chief of Staff for the U.S. commercial operations and customer business unit where he was a member of the business unit leadership team, and responsible for developing the strategic plan with a focus on the evolving role of payers, physicians, patients, and pharmacists in the U.S. His next step in the U.S. in-line organization was as a marketer on the Celebrex team where he developed an early digital marketing campaign, increasing pull-through of the video detailing platform
In 2009, Nate returned to PDA and was shortly thereafter asked to lead the Primary Care and Oncology teams. During his tenure in PDA Nate focused on many internal investment opportunities, but was excited to assume leadership of the Business Development Evaluation (BDE) team in 2013 so that he could practice similar analytical skills but with a focus on the external environment and partnering with companies outside Pfizer. In this role, Nate was also asked to help with the 2013 corporate strategic plan. These corporate strategy efforts, combined with his broad experience across the enterprise, set Nate up to assume his current role as head of both Corporate Strategy and BDE – a role he assumed at the start of 2014.
Nate received a B.A. in International Relations from American University and an M.B.A. in Finance and Strategy from Cornell University. He lives in New York City, and enjoys spending weekends with his partner and two dogs at the beaches on Long Island.
Dr. Khaled El Emam is the founder and CEO of Privacy Analytics, Inc. As an entrepreneur, Khaled helped found five companies involved with data management and data analytics. He has worked in technical and management positions in academic and business settings in England, Scotland and Japan.
Khaled is also a senior scientist at the Children's Hospital of Eastern Ontario (CHEO) Research Institute and Director of the multi-disciplinary Electronic Health Information Laboratory (EHIL) team, conducting academic research on de-identification and re-identification risk. He is a world-renowned expert in statistical de-identification and re-identification risk. He is one of only a handful of individual experts in North America known to be qualified to certify the anonymization of Protected Health Information under the HIPAA privacy law.
In 2003 and 2004, Khaled was ranked as the top systems and software engineering scholar worldwide by the Journal of Systems and Software based on his research on measurement and quality evaluation and improvement.
Previously, Khaled was a Senior Research Officer at the National Research Council of Canada. He also served as the head of the Quantitative Methods Group at the Fraunhofer Institute in Kaiserslautern, Germany.
Khaled was one of the first Privacy by Design Ambassadors recognized by the Ontario Information and Privacy Commissioner. He holds the Canada Research Chair in Electronic Health Information at the University of Ottawa and is an Associate Professor in the Faculty of Medicine at the University. He has a PhD from the Department of Electrical and Electronics Engineering, King's College, at the University of London, England.
Dan has spent his entire career in the healthcare and life sciences industry, including roles in entrepreneurship, venture capital and investment banking. He was formerly a member of the early stage healthcare and life sciences investment teams at Arboretum Ventures and Point Judith Capital, a Partner at Rose Ventures, and a member of the healthcare investment banking group at Credit Suisse First Boston. He is also the co-founder of two medical technology companies and an advisor to LuggageForward. Dan holds a B.A. in mathematics and economics from Middlebury College and an M.B.A. from the Tuck School of Business at Dartmouth.